Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
08:15am, Tuesday, 04'th Mar 2025
Sarepta Therapeutics' stock is at 52-week lows despite strong Q4 earnings and promising clinical updates, reflecting broader biotech sector challenges and investor sentiment. Q4 2024 earnings showed 7
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
09:00am, Friday, 28'th Feb 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
09:45am, Thursday, 27'th Feb 2025
SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
11:48pm, Wednesday, 26'th Feb 2025
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communi
Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates
06:25pm, Wednesday, 26'th Feb 2025
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $0.47 per share a year ago.
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
04:05pm, Wednesday, 26'th Feb 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ful
Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:01am, Wednesday, 26'th Feb 2025
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround
10:35am, Monday, 17'th Feb 2025
The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
08:30am, Friday, 14'th Feb 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior sec
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
08:30am, Wednesday, 12'th Feb 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
08:30am, Monday, 10'th Feb 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRP
2 Growth Stocks to Buy Hand Over Fist in February
09:10am, Sunday, 09'th Feb 2025
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
08:45am, Monday, 03'rd Feb 2025
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline results from Part 2 of EMBARK
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
01:23pm, Thursday, 16'th Jan 2025
Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by the gene therapy. Despite past valuation con
